Epoxyquinol B, a fungal metabolite with a potent antiangiogenic activity [1]

Journal of Antibiotics

Volumn 55, Issue 9, 2002, Pages 829-831

  Kakeya, Hideaki ^a   Onose, Rie ^a   Yoshida, Arika ^a   Koshino, Hiroyuki ^a   Osada, Hiroyuki ^a  

^a RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPOXYQUINOL A; EPOXYQUINOL B; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PURIFICATION; DRUG STRUCTURE; ENDOTHELIUM CELL; FUNGAL METABOLISM; HUMAN; HUMAN CELL; LETTER; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0036749138     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.7164/antibiotics.55.829     Document Type: Letter

References (13)

1. Folkman, J.: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1: 27-31, 1995
2. Fan, T. P.; R. Jaggar & R. Bicknell: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. 16: 57-66, 1995
3. Risau, W.: Mechanism of angiogenesis. Nature 386: 671-674, 1997
4. Isner, J. M. & T. Asahara: Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103: 1231-1236, 1999
5. Kuwano, M.; J. Fukushi, M. Okamoto, A. Nishie, H. Goto, T. Ishibashi & M. Ono: Angiogenesis factors. Intern. Med. 40: 565-572, 2001
6. Shibuya, M.: Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J. Biochem. Cell Biol. 33: 409-420, 2001
7. Ferrara, N. & T. Davis-Smyth: The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25, 1997
8. Gasparini, G.: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58: 17-38, 1998
9. Kakeya, H.; R. Onose, H. Koshino, A. Yoshida, K. Kobayashi, S.-I. Kageyama & H. Osada: Epoxyquinol A, a highly functionalized pentaketide dimer with antiangiogenic activity isolated from fungal metabolites. J. Am. Chem. Soc. 124: 3496-3497, 2002
10. Shoji, M.; J. Yamaguchi, H. Kakeya, H. Osada & Y. Hayashi: Total synthesis of (+)-epoxyquinols A and B. Angew. Chem. Int. Ed. 41: 3192-3194, 2002
11. Dvorak, H. F.; L. F. Brown, M. Detmar & A. M. Dvorak: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Path. 146: 1029-1039, 1995
12. Sun, L.; N. Tran, F. Tang, H. App, P. Hirth, G. McMahon & C. Tang: Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 41: 2588-2603, 1998
13. Shaheen, R. M.; D. W. Davis, W. Liu, B. K. Zebrowski, M. R. Wilson, C. D. Bucana, D. J. Mcconkey, G. Mcmahon & L. M. Ellis: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59: 5412-5416, 1999